Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Dec 17;12(12):CD004349.
doi: 10.1002/14651858.CD004349.pub3.

Blood pressure targets in adults with hypertension

Jose Agustin Arguedas  1 , Viriam Leiva  2 , James M Wright  3
Affiliations
Meta-Analysis

Blood pressure targets in adults with hypertension

Jose Agustin Arguedas et al. Cochrane Database Syst Rev. .

Abstract

Background: This is the first update of this review first published in 2009. When treating elevated blood pressure, doctors usually try to achieve a blood pressure target. That target is the blood pressure value below which the optimal clinical benefit is supposedly obtained. "The lower the better" approach that guided the treatment of elevated blood pressure for many years was challenged during the last decade due to lack of evidence from randomised trials supporting that strategy. For that reason, the standard blood pressure target in clinical practice during the last years has been less than 140/90 mm Hg for the general population of patients with elevated blood pressure. However, new trials published in recent years have reintroduced the idea of trying to achieve lower blood pressure targets. Therefore, it is important to know whether the benefits outweigh harms when attempting to achieve targets lower than the standard target.

Objectives: The primary objective was to determine if lower blood pressure targets (any target less than or equal to 135/85 mm Hg) are associated with reduction in mortality and morbidity as compared with standard blood pressure targets (less than or equal to 140/ 90 mm Hg) for the treatment of patients with chronic arterial hypertension. The secondary objectives were: to determine if there is a change in mean achieved systolic blood pressure (SBP) and diastolic blood pressure (DBP associated with "lower targets" as compared with "standard targets" in patients with chronic arterial hypertension; and to determine if there is a change in withdrawals due to adverse events with "lower targets" as compared with "standard targets", in patients with elevated blood pressure.

Search methods: The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to May 2019: the Cochrane Hypertension Specialised Register, CENTRAL (2019, Issue 4), Ovid MEDLINE, Ovid Embase, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions.

Selection criteria: Randomised controlled trials (RCTs) comparing patients allocated to lower or to standard blood pressure targets (see above).

Data collection and analysis: Two review authors (JAA, VL) independently assessed the included trials and extracted data. Primary outcomes were total mortality; total serious adverse events; myocardial infarction, stroke, congestive heart failure, end stage renal disease, and other serious adverse events. Secondary outcomes were achieved mean SBP and DBP, withdrawals due to adverse effects, and mean number of antihypertensive drugs used. We assessed the risk of bias of each trial using the Cochrane risk of bias tool and the certainty of the evidence using the GRADE approach. MAIN RESULTS: This update includes 11 RCTs involving 38,688 participants with a mean follow-up of 3.7 years. This represents 7 new RCTs compared with the original version. At baseline the mean weighted age was 63.1 years and the mean weighted blood pressure was 155/91 mm Hg. Lower targets do not reduce total mortality (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.86 to 1.05; 11 trials, 38,688 participants; high-certainty evidence) and do not reduce total serious adverse events (RR 1.04, 95% CI 0.99 to 1.08; 6 trials, 18,165 participants; moderate-certainty evidence). This means that the benefits of lower targets do not outweigh the harms as compared to standard blood pressure targets. Lower targets may reduce myocardial infarction (RR 0.84, 95% CI 0.73 to 0.96; 6 trials, 18,938 participants, absolute risk reduction (ARR) 0.4%, number needed to treat to benefit (NNTB) 250 over 3.7 years) and congestive heart failure (RR 0.75, 95% CI 0.60 to 0.92; 5 trials, 15,859 participants, ARR 0.6%, NNTB 167 over 3.7 years) (low-certainty for both outcomes). Reduction in myocardial infarction and congestive heart failure was not reflected in total serious adverse events. This may be due to an increase in other serious adverse events (RR 1.44, 95% CI 1.32 to 1.59; 6 trials. 18,938 participants, absolute risk increase (ARI) 3%, number needed to treat to harm (NNTH) 33 over four years) (low-certainty evidence). Participants assigned to a "lower" target received one additional antihypertensive medication and achieved a significantly lower mean SBP (122.8 mm Hg versus 135.0 mm Hg, and a lower mean DBP (82.0 mm Hg versus 85.2 mm Hg, than those assigned to "standard target".

Authors' conclusions: For the general population of persons with elevated blood pressure, the benefits of trying to achieve a lower blood pressure target rather than a standard target (≤ 140/90 mm Hg) do not outweigh the harms associated with that intervention. Further research is needed to see if some groups of patients would benefit or be harmed by lower targets. The results of this review are primarily applicable to older people with moderate to high cardiovascular risk. They may not be applicable to other populations.

PubMed Disclaimer

Conflict of interest statement

JAA has lectured on this subject in activities organised by Astra‐Zeneca and MSD, neither of which participated in the content of the talks or in the preparation of this work.

VL and JMW have no conflict to declare.

Figures

1
1
6Study flow diagram.
2
2
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 1: Total mortality
1.2
1.2. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 2: CV mortality
1.3
1.3. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 3: Non‐CV mortality
1.4
1.4. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 4: Total serious adverse events
1.5
1.5. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 5: Myocardial infarction
1.6
1.6. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 6: Stroke
1.7
1.7. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 7: Congestive heart failure
1.8
1.8. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 8: End‐stage renal failure
1.9
1.9. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 9: All other serious adverse events
1.10
1.10. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 10: Systolic blood pressure achieved
1.11
1.11. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 11: Diastolic blood pressure achieved
1.12
1.12. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 12: Withdrawals due to adverse events
1.13
1.13. Analysis
Comparison 1: Low vs Standard BP Target, Outcome 13: Number of antihypertensive drugs used per patient
See this image and copyright information in PMC

Update of

References

References to studies included in this review

ABCD (H) 2000 {published and unpublished data}
    1. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54-B64. - PubMed
ACCORD 2010 {published data only (unpublished sought but not used)}
    1. The ACCORD Study Group. Effects of intensive blood-pressure control in type-2 diabetes mellitus. New England Journal of Medicine 2010;362:1575-85. - PMC - PubMed
Cardio‐Sis 2008 {published data only (unpublished sought but not used)}
    1. Verdecchia P, Staessen JA, Angeli F, on behalf of the Cardio-Sis Investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open label randomised trial. Lancet 2009;374:525-33. - PubMed
HOT 1998 {published and unpublished data}
    1. Hansson L, for the HOT Study Group. The Hypertension Optimal Treatment Study (The HOT Study). Blood Pressure 1993;2:62-8. - PubMed
    1. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351(9118):1755-62. - PubMed
    1. Hansson L, Zanchetti A, for the HOT Study Group. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability with special reference to age and gender. Blood Pressure 1995;4:313-9. - PubMed
    1. Hansson L, Zanchetti A, for the HOT Study Group. The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure 1997;6:313-7. - PubMed
    1. Hansson L, Zanchetti A for the HOT Study. The Hypertension Optimal Treatment (HOT) Study. Patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure 1994;3:322-7. - PubMed
PAST‐BP 2016 {published data only (unpublished sought but not used)}
    1. Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor C, Martin U, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke-Blood Pressure) randomized controlled trial. BMJ 2016;352:i708. - PMC - PubMed
REIN‐2 2005 {published data only (unpublished sought but not used)}
    1. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al, REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised, controlled trial. Lancet 2005;365(9463):939-46. - PubMed
Schrier 2002 {published data only (unpublished sought but not used)}
    1. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven year prospective randomized trial. Journal of the American Society of Nephrology 2002;13(7):1733-9. - PubMed
SMAC‐AF 2017 {published data only (unpublished sought but not used)}
    1. Parkash R, Wells GA, Sapp JL, Healey JS, Tardif JC, Greiss I, et al. Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation. A randomized, open label clinical trial (SMAC-AF Substrate Modification with Aggressive Blood Pressure Control). Circulation 2017;135(19):1788-98. - PubMed
SPRINT 2015 {published data only (unpublished sought but not used)}
    1. The SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. New England Journal of Medicine 2015;373(22):2103-16. - PMC - PubMed
SPS3 2013 {published data only (unpublished sought but not used)}
    1. The SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382(9891):507-15. - PMC - PubMed
Toto 1995 {published data only}
    1. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney International 1995;48(3):851-9. - PubMed

References to studies excluded from this review

AASK 2002 {published data only}
    1. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al, African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002;288(19):2421-31. - PubMed
ABCD‐2V 2006 {published data only}
    1. Estacio RO, Coll JR, Tran ZV, Schrier RX. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. American Journal of Hypertension 2006;19(12):1241-8. - PubMed
ABCD‐N 2002 {published data only}
    1. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney International 2002;61:1086-97. - PubMed
ATACH‐2 2016 {published data only}
    1. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al, ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. New England Journal of Medicine 2016;375(11):1033-43. - PMC - PubMed
BBB 1994 {published data only}
    1. Hansson L for the BBB Study Group. The BBB Study Group: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in "well treated" hypertensive patients. Blood Pressure 1994;3(4):248-54. - PubMed
    1. The BBB Study Group. The BBB study: a prospective randomized study of intensified antiihypertensive treatment. Journal of Hypertension 1988;6(9):693-7. - PubMed
CHIPS 2015 {published data only}
    1. Magee LA, Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. New England Journal of Medicine 2015;372(5):407-17. - PubMed
HDS 1996 {published data only}
    1. Hypertension in Diabetes Study Group. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control. Diabetologia 1996;39(12):1554-61. - PubMed
HOMED‐BP 2012 {published data only}
    1. Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research 2012;35:1102-10. - PubMed
JATOS 2008 {published data only}
    1. JATOS Study Group. Principal results of the Japanese Trial to Assess Optimal Systolic blood pressure in elderly hypertensive patients (JATOS). Hypertension Research 2008;31(12):2115-27. - PubMed
Lewis 1999 {published data only}
    1. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect on intensive blood pressure control on the course of type 1 diabetic nephropathy. American Journal of Kidney Diseases 1999;34(5):809-17. - PubMed
MDRD 1995 {published data only}
    1. Peterson JC, Adler S, Burkart KM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Annals of Internal Medicine 1995;123(10):754-62. - PubMed
    1. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Annals of Internal Medicine 2005;142(5):342-51. - PubMed
SANDS 2008 {published data only}
    1. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes. JAMA 2008;299(14):1678-89. - PMC - PubMed
Solomon 2010 {published data only}
    1. Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension 2010;55(2):241-8. - PubMed
Steno‐2 2003 {published data only}
    1. Goede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003;348(5):383-93. - PubMed
UKPDS 1998 {published data only}
    1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. - PMC - PubMed
VALISH 2010 {published data only}
    1. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010;56(2):196-202. - PubMed
Wei 2013 {published data only}
    1. Wei Y, Jin Z, Shen G, Zhao X, Yang W, Zhong Y, et al. Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. Journal of Clinical Hypertension (Greenwich) 2013;15(6):420-7. - PMC - PubMed

Additional references

AACE 2019
    1. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 Executive Summary. Endocrine Practice 2019;25(1):69-100. - PubMed
ACC/AHA 2017
    1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71(6):e13-e115. - PubMed
ADA 2016
    1. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care 2016;39(Suppl1):S60-71. - PubMed
ADA 2019
    1. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes - 2019. Diabetes Care 2019;42(suppl 1):S103-S123. - PubMed
Agarwal 2017
    1. Agarwal R. Implications of blood pressure measurement technique for implementation of Systolic Blood Pressure Intervention Trial (SPRINT). Journal of the American Heart Association 2017;6(2):e004536. - PMC - PubMed
AHA 2007
    1. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115(21):2761-88. - PubMed
Arguedas 2010
    1. Arguedas JA. Blood pressure targets: are clinical guidelines wrong? Current Opinion in Cardioliology 2010;25(4):350-4. - PubMed
Arguedas 2013
    1. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No: CD008277. [DOI: 10.1002/14651858.CD008277.pub2] - DOI - PMC - PubMed
ASH/ISH 2014
    1. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guideline for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. Journal of Hypertension 2014;32(1):3-15. - PubMed
Attar 2019
    1. Attar A, Sayadi M, Jannati M. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: a secondary analysis of the SPRINT trial. European Journal of Preventive Cardiology 2019;26:238-45. - PubMed
Bangalore 2010
    1. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European Heart Journal 2010;31(23):2897-908. - PubMed
Bangalore 2017
    1. Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, et al. Optimal systolic blood pressure target after SPRINT: Insights from a network meta-analysis of randomized trials. Annals of Internal Medicine 2017;130:707-19. - PubMed
Bassler 2010
    1. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. Stopping randomized trials early for benefit and estimation of treatment effects. Systematic review and meta-regression analysis. JAMA 2010;303:1180-7. - PubMed
BHS 2004
    1. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al, BHS guidelines working party, for the British Hypertension Society. British Hypertension Society Guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40. - PMC - PubMed
BPLTTC 2003
    1. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35. - PubMed
BPLTTC 2014
    1. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384:591-8. - PubMed
Brunstrom 2016
    1. Brunstrôm M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016;352:i717. - PMC - PubMed
Bundy 2017
    1. Bundy JA, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality. A systematic review and network meta-analysis. JAMA Cardiology 2017;2(2):775-81. - PMC - PubMed
Chi 2018
    1. Chi G, Jamil A, Jamil U, Balouch MA, Marszalek J, Kahe F, et al. Effect of intensive versus standard blood pressure control on major adverse cardiac events and serious adverse events: a bivariate analysis of randomized controlled trials. Clinical and Experimental Hypertension 2018;40:160-7. [DOI: 10.1080/10641963.2018.1462373] - PubMed
Cipriani 2013
    1. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Annals of Internal Medicine 2013;159:130-7. - PubMed
Diao 2012
    1. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No: CD006742. [DOI: 10.1002/14651858.CD006742.pub2] - DOI - PMC - PubMed
Dorresteijn 2012
    1. Dorresteijn JA, Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FL, Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease. J-curve revisited. Hypertension 2012;59(1):14-21. - PubMed
Drazen 2015
    1. Drazen JM, Morrissey S, Campion EW, Jarcho JA. A SPRINT to the finish. New England Journal of Medicine 2015;373:2174-5. - PubMed
ESC/ESH 2018
    1. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018;39:3021-104. - PubMed
ESH‐ESC 2007
    1. Mancia G, De Backer G, Domiiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2007;25(6):1105-87. - PubMed
Ettehad 2016
    1. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67. - PubMed
Filippone 2011
    1. Filippone EJ, Foy A, Newman E. Goal directed antihypertensive therapy: lower may not always be better. Cleveland Clinic Journal of Medicine 2011;78:123-33. - PubMed
Grossman 2011
    1. Grossman E. Blood pressure: the lower, the better. The con side. Diabetes Care 2011;34 (suppl 2):308-12. - PMC - PubMed
Gueyffier 2001
    1. Gueyffier F. Observational epidemiological studies: values and limitations. Journal of Hypertension 2001;21:673-5. - PubMed
Heimark 2018
    1. Heimark S, Mariampillai JE, Narkiewicz K, Nilsson PM, Kjeldsen SE. Which target blood pressure in year 2018? Evidence form recent clinical trials. High Blood Pressure & Cardiovascular Prevention 2018;25(2):151-8. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2019
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook. - PMC - PubMed
Hypertension Canada 2020
    1. Rabi DE, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension Canada's 2020 Comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Canadian Journal of Cardiology 2020;36(5):596-624. - PubMed
Jackson 2005
    1. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005;365:434-41. - PubMed
JNC 7 2003
    1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. - PubMed
JNC 8 2014
    1. James PA, Oparil S, Carter BL, et al. Evidence based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20. - PubMed
K/DOQI 2004
    1. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. American Journal of Kidney Disease 2004;43 (5 Suppl 1):S1-290. - PubMed
Kannel 1996
    1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6. - PubMed
Kaul 2018
    1. Kaul S. How strong is the evidence to support blood pressure treatment goal of 130/80 mm Hg? Circulation 2018;138:2594-6. - PubMed
Kernan 2014
    1. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45(7):2160-236. - PubMed
Kjeldsen 2016
    1. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension 2016;67(5):808-12. - PubMed
Laurent 2004
    1. Laurent S. Guidelines from the British Hypertension Society. The lower the pressure the better. BMJ 2004;328:593-4. - PMC - PubMed
Laurent 2016
    1. Laurent S, Boutouyrie P. Blood pressure lowering trials: wrapping up the topic? Lancet 2016;387:923-4. - PubMed
Law 2009
    1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. - PMC - PubMed
Lonn 2016
    1. Lonn EM, Yusuf S. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to < 120/80 mm Hg target? An antagonist view from the HOPE-3 Trial (Heart Outcomes Evaluation-3). Circulation 2016;134:1311-3. - PubMed
Lund‐Johansen 2003
    1. Lund-Johansen P. Intensive blood pressure treatment: beneficial for all but the smoking hypertensives? Journal of Hypertension 2003;21:697-700. - PubMed
Lv 2012
    1. Lv JC, Neal B, Ehteshami P, Ninomiya T, Woodward M, Rodgers A, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLOS Medicine 2012;9:e1001293. - PMC - PubMed
MacMahon 2001
    1. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001;357:455-62. - PubMed
Malhotra 2017
    1. Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5. A systematic review and meta-analysis. JAMA Internal Medicine 2017;177:1498-505. - PMC - PubMed
Mancia 2011
    1. Mancia G, Grassi G, Zanchetti A. Antihypertensive treatment and blood pressure in diabetic and non-diabetic patients. The lower the better? Diabetes Care 2011;34 (Suppl 2):304-7. - PMC - PubMed
Mancia 2013
    1. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension; the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013;31(7):1281-357. - PubMed
Marianpilla 2016
    1. Mariampillai JE, Eskås PA, Heimark S, Kjeldsen SE, Narkiewicz K, Mancia G. A case for less intensive blood pressure control: It matters to achieve target blood pressure early and sustained below 140/90 mm Hg. Progress in Cardiovascular Diseases 2016;59:209-18. - PubMed
Musini 2019
    1. Musini VM, Tejani AM, Bassett K, Puil L, Wright JM. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No: CD000028. [DOI: 10.1002/14651858.CD000028.pub3] - DOI - PMC - PubMed
NICE 2011
    1. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management: clinical guideline 127. https://www.nice.org.uk/guidance/cg127/chapter/1-recommendations (accessed Jan 15, 2016).
NICE 2019
    1. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. www.nice.org.uk/guidance/ng136, 2019. - PubMed
ONTARGET 2008
    1. ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. New England Journal of Medicine 2008;358:1547-59. - PubMed
Oparil 2016
    1. Oparil S, Lewis CE. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to < 120/80 mm Hg target? A protagonist view from the SPRINT Trial (Systolic Blood Pressure Intervention Trial). Circulation 2016;134:1308-10. - PMC - PubMed
Ortiz 2016
    1. Ortiz E, James PA. Let's not sprint to judgement about new blood pressure goals. Annals of Internal Medicine 2016;164:692-3. - PubMed
Parati 2011
    1. Parati G, Bilo G, Ochoa JE. Benefits of tight blood pressure control in diabetic patients with hypertension. Importance of early and sustained implementation of effective treatment strategies. Diabetes Care 2011;34 (Suppl 2):S297-303. - PMC - PubMed
Perkovic 2015
    1. Perkovic V, Rodgers A. Redefining blood-pressure targets. SPRINT starts the marathon. New England Journal of Medicine 2015;373:2175-8. - PubMed
Prospective Studies Collaboration 2002
    1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13. - PubMed
Prospective Studies Collaboration 2007
    1. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39. - PubMed
Rapsomaniki 2014
    1. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014;383:1899-911. - PMC - PubMed
Saiz 2020
    1. Saiz LC, Gorricho J, Garjón J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database of Systematic Reviews 2020, Issue 9. Art. No: CD010315. [DOI: 10.1002/14651858.CD010315.pub4] - DOI - PMC - PubMed
Schunemann 2019a
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidenceIn: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Schunemann 2019b
    1. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Sexton 2017
    1. Sexton DJ, Canney M, O'Connell MD, Moore P, Little MA, O'Seaghdha CM, et al. Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT. JAMA International Medicine 2017;177:1385-7. - PMC - PubMed
Sleight 2009
    1. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al, ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial study. Journal of Hypertension 2009;27:1360-9. - PubMed
Stamler 1993
    1. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Archives of Internal Medicine 1993;153(5):598-615. - PubMed
Stokes 1987
    1. Stokes J 3rd, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB. The relative importance of selective risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years. 30 years of follow-up in the Framingham Study. Circulation 1987;75(Suppl V):V65-V73. - PubMed
Sundström 2015
    1. Sundström J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Annals of Internal Medicine 2015;162:184-91. - PubMed
Thomopoulos 2014
    1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk – overview and meta-analyses of randomized trials. Journal of Hypertension 2014;32:2305-14. - PubMed
Thomopoulos 2016 a
    1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials. J Hypertension 2016;34:613-22.. - PubMed
Thomopoulos 2016 b
    1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs discontinuations because of adverse drug events. Journal of Hypertension 2016;34:1451-63. - PubMed
Tsai 2017
    1. Tsai WC, Wu HY, Peng YS, Yang JY, Chen HY, Chiu YL, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease. A systematic review and meta-analysis. JAMA Intern Med 2017;177:792-9. - PMC - PubMed
Verdecchia 2016
    1. Verdecchia P, Angeli F, Gentile G, Reboldi G. More versus less intensive blood pressure-lowering strategy. Cumulative evidence and trial sequential analysis. Hypertension 2016;68:642-53. - PubMed
Viele 2016
    1. Viele K, McGlothlin A, Broglio K. Interpretation of clinical trials that stopped early. JAMA 2016;315:1646-7. - PubMed
Voko 1999
    1. Vokó Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999;34(6):1181-5. - PubMed
WHO/ISH 2003
    1. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension 2003;21:1983-92. - PubMed
Xie 2016
    1. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43. - PubMed
Yeh 2015
    1. Yeh JS. Blood-pressure control. New England Journal of Medicine 2015;373:2180-2. - PubMed
Zanchetti 2003
    1. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, et al, HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? Journal of Hypertension 2003;21(4):797-804. - PubMed
Zanchetti 2009
    1. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? Journal of Hypertension 2009;27:1509-20. - PubMed
Zanchetti 2014
    1. Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, et al. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. Journal of Hypertension 2014;32(9):1741-50. - PubMed
Zanchetti 2015
    1. Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension. A critical reapparaisal. Circulation Research 2015;116(6):1058-73. - PubMed

References to other published versions of this review

Arguedas 2003
    1. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No: CD004349. [DOI: 10.1002/14651858.CD004349] - DOI - PubMed
Arguedas 2004
    1. Arguedas JA. Blood pressure targets in the treatment of patients with elevated blood pressure. Master's Thesis, Department of Pharmacology & Therapeutics, University of British Columbia July 2004.
Arguedas 2009
    1. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD004349. [DOI: 10.1002/14651858.CD004349] - DOI - PubMed

Publication types

MeSH terms

Substances